CA2368937A1 - Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux - Google Patents

Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux Download PDF

Info

Publication number
CA2368937A1
CA2368937A1 CA002368937A CA2368937A CA2368937A1 CA 2368937 A1 CA2368937 A1 CA 2368937A1 CA 002368937 A CA002368937 A CA 002368937A CA 2368937 A CA2368937 A CA 2368937A CA 2368937 A1 CA2368937 A1 CA 2368937A1
Authority
CA
Canada
Prior art keywords
human
ischemia
glycoprotein
alpha
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002368937A
Other languages
English (en)
Inventor
Kevin J. Tracey
Haichao Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Shore Long Island Jewish Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368937A1 publication Critical patent/CA2368937A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention concerne des procédés et des compositions pharmaceutiques de la glycoprotéine humaine fétuine ou .alpha.2-HS glycoprotéine ou ses fragments utiles pour limiter les lésions tissulaires associées à l'ischémie, et plus particulièrement à des accidents vasculaires cérébraux ou à l'infarctus du myocarde.
CA002368937A 1999-04-13 2000-04-13 Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux Abandoned CA2368937A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12928899P 1999-04-13 1999-04-13
US60/129,288 1999-04-13
PCT/US2000/010002 WO2000060943A1 (fr) 1999-04-13 2000-04-13 Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux

Publications (1)

Publication Number Publication Date
CA2368937A1 true CA2368937A1 (fr) 2000-10-19

Family

ID=22439301

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368937A Abandoned CA2368937A1 (fr) 1999-04-13 2000-04-13 Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux

Country Status (5)

Country Link
EP (1) EP1191845A4 (fr)
JP (1) JP2002541162A (fr)
AU (1) AU766910B2 (fr)
CA (1) CA2368937A1 (fr)
WO (1) WO2000060943A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720311B2 (en) * 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US20030044400A1 (en) * 2001-05-22 2003-03-06 Jenny Yu Composition and method for treating cells
JP4426929B2 (ja) * 2004-03-25 2010-03-03 株式会社アミンファーマ研究所 脳卒中・無症候性脳梗塞のスクリーニング方法
EP4117706A1 (fr) 2020-03-11 2023-01-18 Universität Bern Fétuine a pour le traitement de troubles rénaux

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113164D0 (en) * 1991-06-18 1991-08-07 Ici Plc Pharmaceutical agent
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel

Also Published As

Publication number Publication date
AU4348500A (en) 2000-11-14
JP2002541162A (ja) 2002-12-03
WO2000060943A1 (fr) 2000-10-19
EP1191845A1 (fr) 2002-04-03
EP1191845A4 (fr) 2002-07-17
AU766910B2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
Takahashi NLRP3 inflammasome as a novel player in myocardial infarction
US5538845A (en) Beta-amyloid peptide production inhibitors and methods for their identification
EP0375736B1 (fr) Fragments d'acide nucleique codant des fragments du proteine humaine liant le mannose
US7060680B2 (en) Morphogen treatments for limiting proliferation of epithelial cells
WO2002096356A2 (fr) Ligand a forte affinite pour le recepteur de la neurotrophine p75
JP2010046088A (ja) 新規なぺプチド類
JP2002539174A (ja) 癌および血管新生関連の疾病の治療のためのｌｄｌ様受容体リガンドを使用する組成物および方法
RU2232594C2 (ru) Комплекс, содержащий ингибирующий остеокластогенез фактор (ocif) и полисахарид
EP1358888A1 (fr) L'Antibiotique peptidique humain LL-37/hCAP-18 est un inducteur de l'angiogénèse
JP3903503B2 (ja) 可溶性ポリペプチド
AU766910B2 (en) Prevention of brain damage in stroke
US7592310B2 (en) Induction of antibiotic proteins and peptides by LAIT/sCD14-protein
EP0680334B1 (fr) Traitement d'ulceres gastro-intestinaux avec des morphogenes
US7186555B1 (en) Prevention of brain damage in stroke
Plager et al. Human eosinophil granule major basic protein and its novel homolog.
Berkenbosch et al. Colocalization of peptide histidine isoleucine amine and corticotropin-releasing factor immunoreactivity in neurons of the rat hypothalamus: a surprising artefact
WO1992010200A1 (fr) Interactions fonctionnelles entre un glial s-100b et des neurones serotoninergiques du systeme nerveux central
AU768715B2 (en) Copper agonist that binds on the copper binding site of APP and/or exerts an inhibiting effect on the release of amyloid A beta peptide
IE83449B1 (en) Cell growth inhibitors
GB2249312A (en) Beta-Galactoside binding proteins
JP3276753B2 (ja) カテプシンｌ特異的阻害ポリペプチド
US20030158115A1 (en) Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
KR20010043088A (ko) 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 ｃＤＮＡ및 그 용도
JP2000086533A (ja) 新規なアレルギー治療剤
US20090291091A1 (en) Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20080414